Webinar: Antiretroviral Therapy – 2021 Update
Facilitated by David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine, Division of Infectious Diseases
University of Washington
May 12, 2021
Objectives
- List recommended 3-drug and 2-drug antiretroviral options for initial therapy
- Summarize available 2-drug maintenance regimens for persons with undetectable HIV RNA levels
- Discuss three new medications: Ibalizumab, Fostemsavir, and Cabotegravir-Rilpivirine
- Describe the mechanism of action for nucleoside reverse translocate transcriptase inhibitors and capsid Inhibitors
Presentation
Slides
Facilitated by David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine, Division of Infectious Diseases
University of Washington
May 12, 2021
Objectives
- List recommended 3-drug and 2-drug antiretroviral options for initial therapy
- Summarize available 2-drug maintenance regimens for persons with undetectable HIV RNA levels
- Discuss three new medications: Ibalizumab, Fostemsavir, and Cabotegravir-Rilpivirine
- Describe the mechanism of action for nucleoside reverse translocate transcriptase inhibitors and capsid Inhibitors